Dr Reddy's Labs

how big is Dr Reddy's Labs?

As of Jun 06, Dr Reddy's Laboratories Ltd has a market capitalization of 110,231.55 Cr, with recent net sales of 32,643.90 Cr and net profit of 5,655.10 Cr over the last four quarters. Shareholder's funds are 28,254.80 Cr, and total assets amount to 37,806.00 Cr as of Mar'24.

Market Cap: As of Jun 06, Dr Reddy's Laboratories Ltd has a market capitalization of 110,231.55 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 32,643.90 Cr, and the sum of Net Profit is 5,655.10 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the reporting period of Mar'24. The Shareholder's Funds amount to 28,254.80 Cr, and the Total Assets are 37,806.00 Cr.

When is the next results date for Dr Reddy's Labs?

No Upcoming Board Meetings

What is the bonus history of the Dr Reddy's Labs?

Dr. Reddy's Laboratories issued a 1:1 bonus on August 28, 2006, allowing shareholders to double their holdings by receiving an additional share for each share owned, with the record date set for August 29, 2006.

Dr. Reddy's Laboratories has a bonus history that includes a notable 1:1 bonus issue announced on August 28, 2006. The record date for this bonus was August 29, 2006. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about the company or its financials, feel free to ask!

Has Dr Reddy's Labs declared dividend?

Yes, Dr Reddy's Laboratories has declared an 800% dividend, amounting to ₹40 per share, with an ex-date of July 16, 2024. The company has demonstrated strong total returns across various periods, with a total return of 15.2% over the past year.

Dr Reddy's Laboratories Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 40<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.62%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.26%, with no dividend return, resulting in a total return of 5.26%.<BR><BR>Over the past year, the price return was 11.89%, the dividend return was 3.31%, leading to a total return of 15.2%.<BR><BR>In the 2-year period, the price return was 42.35%, the dividend return was 8.21%, culminating in a total return of 50.56%.<BR><BR>For the last 3 years, the price return was 53.12%, with a dividend return of 12.94%, resulting in a total return of 66.06%.<BR><BR>In the 4-year timeframe, the price return was 25.6%, the dividend return was 12.49%, giving a total return of 38.09%.<BR><BR>Lastly, over the past 5 years, the price return was 63.89%, with a dividend return of 20.41%, leading to a total return of 84.3%.<BR><BR>Overall, Dr Reddy's Laboratories has declared a substantial dividend while also showing strong total returns across multiple periods, indicating a positive financial performance for the company.

Who are the peers of the Dr Reddy's Labs?

Dr Reddy's Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci, Lupin, Abbott India, and Aurobindo Pharma. In terms of performance, Divi's Lab leads with a 1-year return of 49.58%, while Dr Reddy's Labs has a return of -5.19%.

Peers: The peers of Dr Reddy's Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci., Lupin, Abbott India, and Aurobindo Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and Aurobindo Pharma, while Average management risk is found at Lupin and Glenmark Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and Lupin, while below average growth is noted for Divi's Lab., Torrent Pharma, and Aurobindo Pharma. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, and Aurobindo Pharma, while good capital structure is found at Torrent Pharma and Lupin, and Glenmark Pharma has average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 49.58%, while Zydus Lifesci. has the lowest at -18.37%, with Dr Reddy's Labs showing a 1-year return of -5.19%, which is higher than Zydus Lifesci. but lower than Divi's Lab. Additionally, Zydus Lifesci., Lupin, and Aurobindo Pharma have negative six-month returns.

Who are in the management team of Dr Reddy's Labs?

As of March 2022, the management team of Dr Reddy's Labs includes G V Prasad (Co-Chairman & Managing Director), K Satish Reddy (Executive Chairman), and several independent directors, including Kalpana Morparia and Leo Puri, among others. This team is responsible for the company's strategic direction and governance.

As of March 2022, the management team of Dr Reddy's Labs includes the following individuals:<BR><BR>1. G V Prasad - Co-Chairman & Managing Director<BR>2. K Satish Reddy - Executive Chairman<BR>3. Kalpana Morparia - Independent Director<BR>4. Shikha Sanjaya Sharma - Independent Director<BR>5. Leo Puri - Independent Director<BR>6. K P Krishnan - Independent Director<BR>7. Pennv Wan - Independent Director<BR>8. K Randhir Singh - Company Secretary & Compliance Officer<BR>9. Arun M. Kumar - Independent Director<BR>10. Claudio Albrecht - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

What does Dr Reddy's Labs do?

Dr Reddy's Laboratories Limited is a global pharmaceutical company that offers affordable and innovative medicines, with a market cap of INR 104,919 Cr and a net profit of INR 15,933 Cr as of March 2025. Key metrics include a P/E ratio of 19.00 and a dividend yield of 1.27%.

Overview:<BR>Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company that provides affordable and innovative medicines, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Dr Reddy's Laboratories was incorporated in the year N/A. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 85,284 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 15,933 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: INR 104,919 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 1.27%<BR>- Debt Equity: -0.03<BR>- Return on Equity: 16.86%<BR>- Price to Book: 3.13<BR><BR>Contact Details:<BR>Address: 8-2-337 Road No 3, Banjara Hills Hyderabad Telangana : 500034<BR>Tel: 91-40-49002900<BR>Email: shares@drreddys.com<BR>Website: http://www.drreddys.com

Who are the top shareholders of the Dr Reddy's Labs?

The top shareholders of Dr Reddy's Labs include promoter G V Prasad with 11.52%, J P Morgan Chase Bank Na as the largest public shareholder at 11.54%, mutual funds holding 12.89%, foreign institutional investors at 25.75%, and individual investors with approximately 8.2%.

The top shareholders of Dr Reddy's Labs include several key players. The majority shareholders are the promoters, with G V Prasad being the promoter with the highest holding at 11.52%. In the public domain, J P Morgan Chase Bank Na holds a significant stake of 11.54%, making it the highest public shareholder. Additionally, mutual funds collectively hold 12.89% through 38 schemes, while foreign institutional investors (FIIs) account for 25.75% with 799 FIIs involved. Individual investors hold around 8.2% of the shares.

Is Dr Reddy's Labs overvalued or undervalued?

As of October 27, 2025, Dr Reddy's Labs is fairly valued with a PE ratio of 18.57, lower than its peers like Sun Pharma and Divi's Lab, despite recent underperformance compared to the Sensex.

As of 27 October 2025, Dr Reddy's Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered fairly valued. Key ratios include a PE ratio of 18.57, an EV to EBITDA ratio of 11.31, and a Price to Book Value of 0.30, which indicate a reasonable valuation compared to its peers.<BR><BR>In comparison to its peers, Dr Reddy's Labs has a lower PE ratio than Sun Pharma (35.43) and Divi's Lab (74.62), both of which are classified as expensive. Additionally, it is on par with Cipla (PE of 23.74) and Zydus Lifesciences (PE of 21.52), which are also attractive. Despite a recent underperformance relative to the Sensex over the past year, where Dr Reddy's returned -1.40% compared to the Sensex's 6.77%, the valuation metrics suggest that the stock is currently fairly valued in the market.

Is Dr Reddy's Labs technically bullish or bearish?

As of November 28, 2025, Dr Reddy's Labs shows a mildly bullish trend based on daily moving averages and weekly Dow Theory, despite mixed signals from weekly MACD and KST indicators.

As of 28 November 2025, the technical trend for Dr Reddy's Labs has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are bearish, suggesting mixed signals. The weekly Dow Theory shows a mildly bullish trend, but the monthly indicators remain mostly bearish or neutral. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory, despite the bearish signals from MACD and KST on the weekly time frame.

How has been the historical performance of Dr Reddy's Labs?

Dr Reddy's Labs has shown consistent growth from Mar'20 to Mar'25, with net sales increasing from 17,517 Cr to 32,643.90 Cr and profit after tax rising from 1,969.90 Cr to 5,703.50 Cr. The company has maintained positive cash flow and expanded its total assets significantly, reflecting strong financial health.

Answer:<BR>The historical performance of Dr Reddy's Labs shows a consistent growth trajectory in net sales, with figures rising from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Total operating income has mirrored this trend, increasing from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Operating profit (PBDIT) has also seen significant growth, climbing from 3,091.00 Cr in Mar'20 to 9,644.40 Cr in Mar'25, although the operating profit margin has fluctuated, peaking at 28.42% in Mar'24 before dropping to 26.26% in Mar'25. Profit before tax has increased from 1,829.60 Cr in Mar'20 to 7,657.80 Cr in Mar'25, while profit after tax has risen from 1,969.90 Cr to 5,703.50 Cr over the same period. The company's total assets have grown from 22,005.40 Cr in Mar'20 to 47,594.10 Cr in Mar'25, reflecting a strong balance sheet, while total liabilities have also increased, from 22,005.40 Cr to 47,594.10 Cr. Cash flow from operating activities has shown a positive trend, increasing from 2,984.00 Cr in Mar'20 to 4,642.00 Cr in Mar'25, contributing to a net cash inflow of 748.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Reddy's Labs has demonstrated robust growth in net sales, which rose from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25, indicating a strong demand for its products. The total operating income followed suit, reflecting the same upward trend. Operating profit (PBDIT) has significantly increased, reaching 9,644.40 Cr in Mar'25, although the operating profit margin experienced some volatility. Profit before tax surged to 7,657.80 Cr, while profit after tax reached 5,703.50 Cr, showcasing the company's improving profitability. The total assets of Dr Reddy's Labs expanded considerably, reflecting its growth strategy, while total liabilities also increased, indicating a corresponding rise in financial obligations. The cash flow from operating activities has remained positive, contributing to a net cash inflow, which further underscores the company's solid financial health and operational efficiency.

Are Dr Reddys Laboratories Ltd latest results good or bad?

Dr. Reddy's Laboratories Ltd. reported disappointing Q4 FY26 results, with a net profit decline of 86.14% and an 11.51% drop in revenue, marking significant operational challenges and raising concerns about business sustainability. The outlook appears negative, prompting caution for investors.

Dr. Reddy's Laboratories Ltd. has reported disappointing results for Q4 FY26, indicating a significant downturn in its financial performance. The company's net profit collapsed by 86.14% year-on-year to ₹220.90 crores, and revenue fell by 11.51% year-on-year to ₹7,546.40 crores. This marks the first time in years that Dr. Reddy's has experienced a double-digit revenue contraction, raising concerns about its business sustainability.<BR><BR>Operating margins also suffered dramatically, plummeting to 5.09% from 23.49% a year ago, which is the lowest in recent history. The decline in operating profit before depreciation, interest, tax, and other income (PBDIT) was staggering, dropping 80.85% year-on-year. The company's reliance on non-operating income to maintain profitability is alarming, as this income accounted for a significant portion of profit before tax.<BR><BR>While Dr. Reddy's had shown strong performance in the earlier quarters of FY26, the Q4 results overshadow these achievements and highlight serious operational challenges. The financial metrics indicate a critical need for management to address the issues affecting margins and revenue. Given these results, the outlook appears negative, and investors may need to exercise caution moving forward.

Should I buy, sell or hold Dr Reddys Laboratories Ltd?

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 21-May, Dr Reddys Laboratories Ltd's stock price is at 1,318.35, down 0.27% after two consecutive days of decline. The drop is linked to reduced investor participation and a 25.8% profit decline over the past year, despite strong long-term performance and high institutional holdings.

As of 21-May, Dr Reddys Laboratories Ltd's stock price is currently at 1,318.35, reflecting a decrease of 3.55 points or 0.27%. The stock has been experiencing a decline, having fallen consecutively for the last two days, resulting in a total drop of 1.12% during this period. Additionally, the stock has underperformed its sector by 0.37% today.<BR><BR>Despite the recent price drop, the stock has shown resilience in the longer term, with a 1-month increase of 8.00% and a year-to-date rise of 3.72%. It is also noteworthy that the stock is trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend over a longer timeframe.<BR><BR>However, a significant factor contributing to the current decline is the falling investor participation, as evidenced by a delivery volume of 7.03 lacs on 20 May, which has decreased by 62.45% compared to the 5-day average. This drop in trading activity may signal a lack of confidence among investors, impacting the stock's performance negatively.<BR><BR>Moreover, while the company maintains a strong management efficiency with a high return on equity (ROE) of 15.68% and is net-debt free, its profits have fallen by 25.8% over the past year, which could be a concern for investors. Despite these challenges, the stock has high institutional holdings at 63.8%, suggesting that larger investors still see potential in the company.<BR><BR>In summary, the recent decline in Dr Reddys Laboratories Ltd's stock price can be attributed to consecutive days of falling prices, reduced investor participation, and concerns over profit declines, despite its strong long-term performance and management efficiency.

Which are the latest news on Dr Reddy's Labs?